Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,447.39 +66.04 (+0.79%) Bitcoin USD
63,093.57 +1,674.19 (+2.73%) CMC Crypto 200
1,307.95 -50.06 (-3.69%)
PFE Jun 2026 23.000 call
| Previous close | 6.50 |
| Open | 6.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 23.00 |
| Expiry date | 2026-06-18 |
| Day's range | 6.50 - 6.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 374 |
GuruFocus.comDecoding Pfizer Inc (PFE): A Strategic SWOT Insight
Insightful Analysis of Pfizer Inc's Financial Health and Strategic Position
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
